BridgeBio Pharma (BBIO) PT Lowered to $45 at Citi
Citi analyst David Lebowitz lowered the price target on BridgeBio Pharma (NASDAQ: BBIO) to $45.00 (from $46.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)